Related Experiment Videos
Absence of significant effects by levamisole on circulating neutrophil levels in normal mice treated with 5-FU
1Oncology and Endocrinology Research, Janssen Research Foundation, Spring House, PA 19477.
Abstract:
When B6C3F1 mice were given a single intravenous (i.v.) injection of 150 mg/kg 5-fluorouracil (5-FU) their levels of circulating neutrophils plummeted, reaching a nadir at 6 to 7 days postdosing and then gradually increasing to normal and above-normal levels. Neutropenia (actual neutrophil count (ANC) below 100 ANC/microliters) extended until 8.7 +/- 0.2 days after 5-FU injection. When these mice were also given levamisole (2.5 mg/kg, po) on days 0-2 the mean time to ANC recovery greater than 100/microliters was 7.7 +/- 0.3 days, (p < 0.05 vs. controls), while IL-1 (2 micrograms/day, ip) positive controls yielded a mean time to > 100 ANC of 6.5 +/- 0.2 days. Although levamisole-treated mice attained normal neutrophil levels one day faster than controls did and this more rapid recovery led to their neutrophil levels being between 2- and 3-fold greater, these differences were not statistically significant. Effects were only manifested on neutrophil recoveries. There were no differences between levamisole-treated mice and controls when recovery rates for platelets, monocytes or lymphocytes were examined. These results demonstrate that levamisole has, at best, only weak myelopoietic properties against 5-FU-induced myelotoxicity in mice.
Insights
Levamisole showed minimal effect in speeding up neutrophil recovery in mice after 5-fluorouracil (5-FU) treatment. This study indicates weak myelopoietic properties of levamisole against 5-FU-induced neutropenia.
Area of Science:
- Immunology
- Pharmacology
- Hematology
Background:
- 5-fluorouracil (5-FU) is a chemotherapy agent known to cause significant neutropenia.
- Neutropenia, a decrease in neutrophil count, increases infection risk in patients undergoing chemotherapy.
- Assessing agents that can mitigate chemotherapy-induced neutropenia is crucial for supportive cancer care.
Purpose of the Study:
- To investigate the potential of levamisole to accelerate neutrophil recovery following 5-fluorouracil-induced myelotoxicity in mice.
- To compare the effects of levamisole with a positive control (IL-1) on neutrophil count recovery.
Main Methods:
- B6C3F1 mice received a single intravenous injection of 5-fluorouracil (150 mg/kg).
- Levamisole (2.5 mg/kg, orally) was administered on days 0-2 post-5-FU injection.
- Actual neutrophil counts (ANC) were monitored to determine the time to recovery (ANC > 100/microliter).
- Recovery rates for platelets, monocytes, and lymphocytes were also examined.
Main Results:
- 5-FU induced severe neutropenia, with neutrophil counts reaching a nadir at 6-7 days and recovery taking over 8 days.
- Levamisole treatment resulted in a mean time to ANC recovery of 7.7 days, which was statistically faster than controls (p < 0.05).
- However, the observed neutrophil levels in levamisole-treated mice were not statistically significant compared to controls, and no effects were seen on platelet, monocyte, or lymphocyte recovery.
Conclusions:
- Levamisole demonstrates only weak myelopoietic properties in accelerating neutrophil recovery after 5-FU-induced myelotoxicity in mice.
- The observed acceleration of neutrophil recovery by levamisole was not statistically significant when compared to controls.
- Levamisole did not impact the recovery of other hematopoietic cell lines, suggesting a limited scope of action.